NCT03129243

Brief Summary

In the current era of assisted reproductive techniques where technology can help overcome defects in sperm function, the value of semen analysis has become even more inaccurate. Initial reports of intracytoplasmic sperm injection revealed its ability to bypass the natural selection process and enable men with severely impaired semen parameters to achieve both clinical pregnancy and live birth

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 23, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 26, 2017

Completed
11 months until next milestone

Study Start

First participant enrolled

April 1, 2018

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 15, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2019

Completed
Last Updated

May 28, 2020

Status Verified

May 1, 2020

Enrollment Period

1.5 years

First QC Date

April 23, 2017

Last Update Submit

May 26, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • clinical pregnancy rate

    4 weeks

Interventions

flowcytometric test where sperm DNA breaks are evaluated indirectly through the DNA denaturability. The assay measures the susceptibility of sperm DNA to acid-induced DNA denaturation in situ, followed by staining with the fluorescence dye acridine orange. By using a flow cytometer 5.000-10.000 sperm can be analyzed within few seconds and thus provide a less subjective result compared to the World health organization analysis where only 1-300 cells are analyzed.

Eligibility Criteria

Age20 Years - 50 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

The study will include all infertile couples undergoing intracytoplasmic sperm injection in The Department of Dermatology and Andrology with assisted reproductive unit at women's health hospital, Assiut University Hospital.

You may qualify if:

  • Infertile male patients with abnormal semen parameters.
  • Normal female partner aged \<38 years.

You may not qualify if:

  • Female patients with obvious infertility factor.
  • Male patients with azoospermia.
  • Male patients with systemic diseases.
  • Male patients receiving cytotoxic therapy.
  • Male patients with genital pathology as cryptorchidism.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ahmed Abbas

Assiut, Cairo Governorate, 002, Egypt

Location

MeSH Terms

Conditions

Infertility, Male

Condition Hierarchy (Ancestors)

Genital Diseases, MaleGenital DiseasesUrogenital DiseasesInfertilityMale Urogenital Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

April 23, 2017

First Posted

April 26, 2017

Study Start

April 1, 2018

Primary Completion

September 15, 2019

Study Completion

October 30, 2019

Last Updated

May 28, 2020

Record last verified: 2020-05

Locations